Atea Current Deferred Revenue from 2010 to 2024
| AVIR Stock | USD 3.77 0.22 6.20% |
Current Deferred Revenue | First Reported 2010-12-31 | Previous Quarter (0.90) | Current Value (0.85) | Quarterly Volatility 77.8 M |
Check Atea Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Atea Pharmaceuticals' main balance sheet or income statement drivers, such as Net Interest Income of 30.7 M, Interest Income of 30.7 M or Depreciation And Amortization of 436.8 K, as well as many indicators such as Price To Sales Ratio of 2.3, Dividend Yield of 0.0 or PTB Ratio of 0.48. Atea financial statements analysis is a perfect complement when working with Atea Pharmaceuticals Valuation or Volatility modules.
Atea | Current Deferred Revenue |
Latest Atea Pharmaceuticals' Current Deferred Revenue Growth Pattern
Below is the plot of the Current Deferred Revenue of Atea Pharmaceuticals over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. Atea Pharmaceuticals' Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Atea Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Current Deferred Revenue | 10 Years Trend |
|
Current Deferred Revenue |
| Timeline |
Atea Current Deferred Revenue Regression Statistics
| Arithmetic Mean | 20,211,333 | |
| Geometric Mean | 27,829 | |
| Coefficient Of Variation | 384.83 | |
| Mean Deviation | 37,487,422 | |
| Median | 200,000 | |
| Standard Deviation | 77,779,467 | |
| Sample Variance | 6049.6T | |
| Range | 301.6M | |
| R-Value | 0.18 | |
| Mean Square Error | 6293.3T | |
| R-Squared | 0.03 | |
| Significance | 0.51 | |
| Slope | 3,208,261 | |
| Total Sum of Squares | 84695T |
Atea Current Deferred Revenue History
About Atea Pharmaceuticals Financial Statements
Atea Pharmaceuticals shareholders use historical fundamental indicators, such as Current Deferred Revenue, to determine how well the company is positioned to perform in the future. Although Atea Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Atea Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Atea Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | (0.90) | (0.85) |
Pair Trading with Atea Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Atea Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Atea Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Atea Stock
| 0.33 | A | Agilent Technologies Fiscal Year End 18th of November 2024 | PairCorr |
The ability to find closely correlated positions to Atea Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Atea Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Atea Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Atea Pharmaceuticals to buy it.
The correlation of Atea Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Atea Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Atea Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Atea Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Atea Stock Analysis
When running Atea Pharmaceuticals' price analysis, check to measure Atea Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atea Pharmaceuticals is operating at the current time. Most of Atea Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Atea Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atea Pharmaceuticals' price. Additionally, you may evaluate how the addition of Atea Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.